
 <p style="margin: 0;">Oregon Health & Science University Hospital and Clinics Provider's Orders</p> <div style="display: flex; align-items: center; margin: 5px 0;"> <div style="writing-mode: vertical-rl; transform: rotate(180deg); font-size: small; margin-right: 5px;">PO9031</div>  </div> <p style="margin: 5px 0; text-align: center; font-size: small;">ADULT AMBULATORY INFUSION ORDER</p> <p style="margin: 0; text-align: center;">Mepolizumab (NUCALA) Subcutaneous Injection</p> <p style="margin: 5px 0; text-align: center; font-size: x-small;">Page 1 of 2</p>	<p style="margin: 0; font-size: small;">ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE</p> <p style="margin: 10px 0; text-align: right; font-size: x-small;"><i>Patient Identification</i></p>
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE	

Weight: _____ kg **Height:** _____ cm

Allergies: _____

Diagnosis Code: _____

Treatment Start Date: _____ **Patient to follow up with provider on date:** _____

****This plan will expire after 365 days at which time a new order will need to be placed****

GUIDELINES FOR ORDERING

1. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with mepolizumab. Decrease corticosteroids gradually, if appropriate.
2. Herpes zoster infections have occurred in patients receiving mepolizumab. Consider varicella vaccination if medically appropriate prior to starting therapy with mepolizumab.
3. Treat patients with pre-existing helminth infections before therapy with mepolizumab. If patients become infected while receiving treatment with mepolizumab and do not respond to anti-helminth treatment, discontinue mepolizumab until parasitic infection resolves.

MEDICATIONS:

mepolizumab (NUCALA) injection, subcutaneous, ONCE

Asthma:

100 mg

Eosinophilic granulomatosis with polyangitis (treatment) Dose:

300 mg (administer as THREE separate 100 mg injections at a distance 5 cm or more apart)

Interval:

Every 4 weeks

NURSING ORDERS:

1. Administer subcutaneously into the upper arm, thigh, or abdomen. Do not inject into skin that is tender, bruised, red, or hard.
2. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declothing (alteplase), and/or dressing changes.
3. Observe patient for hypersensitivity reactions, including anaphylaxis, for 30 minutes after administration.



Oregon Health & Science University
Hospital and Clinics Provider's Orders

OHSU
Health

ADULT AMBULATORY INFUSION ORDER

**Mepolizumab (NUCALA)
Subcutaneous Injection**

Page 2 of 2

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE

HYPERSENSITIVITY MEDICATIONS:

1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydramine (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

By signing below, I represent the following:

I am responsible for the care of the patient (*who is identified at the top of this form*);

I hold an active, unrestricted license to practice medicine in: Oregon _____ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

My physician license Number is # _____ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: _____	Date/Time: _____
Printed Name: _____	Phone: _____ Fax: _____

Please check the appropriate box for the patient's preferred clinic location:

Hillsboro Medical Center
 Infusion Services
 364 SE 8th Ave, Medical Plaza Suite 108B
 Hillsboro, OR 97123
 Phone number: (503) 681-4124
 Fax number: (503) 681-4120

Adventist Health Portland
 Infusion Services
 10123 SE Market St
 Portland, OR 97216
 Phone number: (503) 261-6631
 Fax number: (503) 261-6756

Mid-Columbia Medical Center
 Celilo Cancer Center
 1800 E 19th St
 The Dalles, OR 97058
 Phone number: (541) 296-7585
 Fax number: (541) 296-7610